GreenPrints Institutional repository of De La Salle Medical and Health Sciences Institut
Not a member yet
6526 research outputs found
Sort by
Jewelry egg box 12
No full text1819-RPA-075https://greenprints.dlshsi.edu.ph/collections_3d/1016/thumbnail.jp
Jewelry egg box 14
No full text1819-RPA-077https://greenprints.dlshsi.edu.ph/collections_3d/1018/thumbnail.jp
Welcome to the Family
No full text1819-RPA-099https://greenprints.dlshsi.edu.ph/collections_3d/1039/thumbnail.jp
A Flower\u27s Whisper
No full text1819-RPA-100https://greenprints.dlshsi.edu.ph/collections_3d/1040/thumbnail.jp
Cj0983 and Cj0090 Lipoproteins Contain Potential Linear Peptide Epitopes for Anti-Campylobacter jejuni Vaccine Applications
No full textAbstract: Campylobacter jejuni, a Gram-negative bacterium, is the major etiologic agent of campylobacteriosis responsible for approximately 90% of reported foodborne infections globally. As a result, alternative approaches such as bacterial vaccines may play pivotal roles in mitigating these bacterial public health concerns. Although there are ongoing studies on the development of vaccine candidates based on antigenic molecules of C. jejuni, the potential of Cj0983 and Cj0090 to be independently considered in the preparation of a protective lipoprotein antigen-based anti-C. jejuni vaccine remains elusive. Herein, the potential linear antigenic epitopes in Cj0983 and Cj0090 from C. jejuni were investigated for possible vaccine applications. Linear peptide epitopes were identified and evaluated for their antigenic and non-allergenic properties using VaxiJen and AllergenFP, respectively. Comprehensive bioinformatics-based in silico analyses revealed that there were 37 B-cell, 371 Class I T-cell, and 365 Class II T-cell peptide epitopes found in Cj0983. In comparison, there were 10 B-cell, 63 Class I T-cell, and 93 Class II T-cell peptide epitopes found in Cj0090. Through PyMOL, selected molecular interactions were screened and predicted between chains of human leukocyte antigen (HLA)-peptide epitope complexes, revealing that H-bonding is the predominant intermolecular force during binding. Our results identified the top three peptide epitopes for Cj0983 (312QNDDYKLNLDLKFKN326, 311TQNDDYKLNLDLKFK325, and 309NITQNDDYKLNLDLKF324) and Cj0090 (98QEVILRKLASDTRAND113, 106ASDTRANDFRLEIKA120, and 113DFRLEIKAK121) which have great potentials as vaccine components and can further be utilized as contributing protein-derived molecules towards advancing anti-C. jejuni vaccine development
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial
No full textBackground: WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. Methods: TRUNCATE-TB was a multi-arm, multi-stage, open-label, randomised controlled trial in which participants aged 18–65 years with rifampicin-susceptible pulmonary tuberculosis were randomly assigned via a web-based system, using permuted blocks, to 24-week standard treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol) or the TRUNCATE management strategy comprising initial 8-week treatment, then post-treatment monitoring and re-treatment where needed. The four 8-week regimens comprised five drugs, modified from standard treatment: high-dose rifampicin and linezolid, or high-dose rifampicin and clofazimine, or bedaquiline and linezolid, all given with isoniazid, pyrazinamide, and ethambutol; and rifapentine, linezolid, and levofloxacin, given with isoniazid and pyrazinamide. Here, we report the efficacy (proportion with unfavourable outcome; and difference from standard treatment, assessed via Bayesian methods) and safety of the 8-week regimens, assessed in the intention-to-treat population. This prespecified exploratory analysis is distinct from the previously reported 96-week outcome of the strategy in which the regimens were deployed. This trial is registered with ClinicalTrials.gov (NCT03474198). Findings: Between March 21, 2018, and March 26, 2020, 675 participants (674 in the intention-to-treat population) were enrolled and randomly assigned to the standard treatment group or one of the four 8-week regimen groups. Two 8-week regimens progressed to full enrolment. An unfavourable outcome (mainly relapse) occurred in seven (4%) of 181 participants on standard treatment; 46 (25%) of 184 on the high-dose rifampicin and linezolid-containing regimen (adjusted difference 21·0%, 95% Bayesian credible interval [BCI] 14·3–28·1); and 26 (14%) of 189 on the bedaquiline and linezolid-containing regimen (adjusted difference 9·3% [4·3–14·9]). Grade 3–4 adverse events occurred in 24 (14%) of 181 participants on standard treatment, 20 (11%) of 184 on the rifampicin-linezolid regimen, and 22 (12%) of 189 on the bedaquiline-linezolid regimen. Interpretation: Efficacy was worse with 8-week regimens, although the difference from standard treatment varied between regimens. Even the best 8-week regimen (bedaquiline-linezolid) should only be used as part of a management strategy involving post-treatment monitoring and re-treatment if necessary. Funding: Singapore National Medical Research Council; UK Department of Health and Social Care; UK Foreign, Commonwealth, and Development Office; UK Medical Research Council; Wellcome Trust; and UK Research and Innovation Medical Research Council
Artwork 017: Common Grind Cafe
No full textFor the price: Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1016/thumbnail.jp
Artwork 087: Synergia
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1086/thumbnail.jp
Artwork 034: Father and Child Bonding
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1033/thumbnail.jp
Artwork 051: Floral Illusion 1
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1050/thumbnail.jp